← Eichor
Study identifier: NCT06531278 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

Condition: Pancreatic Cancer Metastatic to Liver  ·  Sponsor: Jiang Long

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

1. Evaluation of adebelimab in combination with irinotecan liposomes, oxaliplatin, fluorouracil, efficacy and safety of leucovorin in the first-line treatment of advanced metastatic pancreatic cancer 2. Construct the model of immunotherapy combined with chemotherapy for the treatment of pancreatic cancer liver metastasis

This description comes directly from the study's public registry record.

Talk to the study team

Long Jiang, MD  ·  18017317460  ·  jiang.long@shgh.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai General HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06531278